Testing a new drug for active inflammatory muscle disease
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system clinical trials.
This trial tests a new drug called nerandomilast in people with active inflammatory muscle disease (myositis) that is not well controlled with current treatments. It aims to see if the drug can improve muscle strength and overall disease activity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older (or the legal adult age in your country).
- You must have a confirmed diagnosis of inflammatory muscle disease (myositis) based on official classification criteria.
- Your muscle disease must be moderate to severe and still active despite current treatment.
- You must be currently taking medication for your muscle disease (background therapy).
- If you are a woman who can become pregnant, you must agree to use highly effective birth control during the trial and for a short period after.
- You cannot have advanced lung disease related to your muscle disease, or severe muscle damage.
- You must not have had major surgery within the past 6 weeks or plan to during the trial.
- You must not have had cancer within the past 5 years, except for certain types of skin cancer or early-stage cervical cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with inflammatory myositis over time to learn more about the condition. If you join, you may receive closer monitoring and contribute to research that could improve future treatments.
This trial looks at treatment strategies for people with idiopathic inflammatory myopathies, which are illnesses where the immune system attacks muscles. It may help improve how treatment is chosen and optimized for this group of conditions, but it specifically excludes several related muscle diseases.
This trial tests an investigational drug called AZD5492 for people with active lupus, inflammatory myositis, or rheumatoid arthritis who haven't responded well to other treatments. It aims to see if the drug is safe and how it works in the body.
This trial is testing a new drug (a JAK inhibitor) for people with rare inflammatory diseases like Behçet's, myositis, or IgG4-related disease that hasn't improved with standard treatments. The goal is to see if it can help control symptoms and reduce inflammation.
This trial tests an experimental medicine (BMS-986553) for people with autoimmune diseases that have not improved with other treatments. It aims to see if the drug is safe and helpful for conditions like lupus, myositis, scleroderma, rheumatoid arthritis, and Sjögren's disease.
This trial is testing an experimental drug for safety in people with certain autoimmune diseases—like myositis, scleroderma, or Sjögren's disease—as well as in healthy volunteers. It aims to find out if the drug is safe enough to study further.
Hear when a new Idiopathic Inflammatory Myopathies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.